The CDE of China granted permission to Accro Bioscience (Suzhou) Limited. Accro Bioscience Inc. for its clinical testing of AC-003, which marks Accro Bioscience Inc.'s first clinical study in China. Accro Bioscience Inc. owns global intellectual property rights of AC-003.
AC-003 is a novel oral small-molecule inhibitor of receptor interacting protein kinase 1(RIPK1) and has the potential for treating idiopathic pulmonary fibrosis (IPF) and graft versus host disease (GVHD).
